Clinical Trials Logo

Filter by:
NCT ID: NCT05822557 Completed - Stroke Clinical Trials

Bolus Pouch Feed Study

Start date: April 1, 2023
Phase: N/A
Study type: Interventional

The primary aim of this study is to evaluate the impact of introducing a new enteral tube feed on health and feeding related quality of life. Secondary aims are to assess ease of use, liking, compliance, gastrointestinal tolerance, nutrient intake, anthropometric changes and safety.

NCT ID: NCT05820984 Completed - Clinical trials for Adequate Reporting in Published Study Protocols of Randomized Controlled Trials

A Short SPIRIT Checklist for Peer Reviewers to Improve the Reporting Quality in Published Articles (SPIRIT-PR)

SPIRIT-PR
Start date: June 1, 2020
Phase: N/A
Study type: Interventional

Transparent and accurate reporting is key, so that readers can adequately interpreting the results of a study. The aim of this project is to evaluate whether reminding peer reviewers of the most important SPIRIT reporting items (including a short explanation of those items) will result in higher adherence to SPIRIT guidelines in published protocols for RCTS. During the standard peer-review process, peer-reviewers will be randomly allocated to use either (i) a short version of the SPIRIT checklist including the ten most important and poorly reported SPIRIT items ; or (ii) no checklist. The aim is to find an intervention which improves the reporting, making it easier for readers to adequately interpret the presented articles.

NCT ID: NCT05820971 Completed - Clinical trials for Adequate Reporting in Randomized Controlled Trials

A Short CONSORT Checklist for Peer Reviewers to Improve the Reporting of Randomised Controlled Trials Published

CONSORT-PR
Start date: June 15, 2019
Phase: N/A
Study type: Interventional

Transparent and accurate reporting is key, so that readers can adequately interpreting the results of a study. Despite improvement with implementation of the CONSORT Statement (CONsolidated Standards for Reporting Trials), there remain major reporting deficiencies in published randomized controlled trials (RCT). The aim of this project is to evaluate whether reminding peer reviewers of the most important CONSORT items (including a short explanation of those items) will result in higher adherence to CONSORT guidelines in published RCTs. During the standard peer-review process, peer-reviewers will be randomly allocated to use either (i) a short version of the CONSORT checklist including the ten most important and poorly reported CONSORT items as defined by a group of experts of the CONSORT Statement (C-short); or (ii) no checklist. The aim is to find an intervention which improves the reporting, making it easier for readers to adequately interpret the presented results.

NCT ID: NCT05817461 Completed - Clinical trials for Cardiovascular Diseases

An ADME Study of [14C]AZD0780 in Healthy Male Subjects

Start date: April 19, 2023
Phase: Phase 1
Study type: Interventional

The Sponsor is developing a new test medicine, AZD0780, with the aim to lower low-density lipoprotein cholesterol (LDL-C, fatty deposits) levels and cardiovascular (heart disease) risk, when given on top of standard care. This two-part healthy volunteer study will try to identify how the test medicine is taken up, broken down and removed from the body. To help investigate this, the test medicine is radiolabelled, which means that the test medicine has a radioactive component (carbon-14; also referred as 14C) which helps us to track where the test medicine is in the body. The safety and tolerability of the test medicine will also be studied. This study will take place at one non-NHS site, enrolling up to 8 male volunteers aged between 30 and 55 years.

NCT ID: NCT05815459 Completed - Clinical trials for Major Depressive Disorder

Mobile Observation Of Depression

MOOD
Start date: July 15, 2022
Phase:
Study type: Observational

The primary aim of this project is to test if OCOsense glasses can function as a digital phenotyping tool derived from behavioural and physiological signals related to facial expression and motion recorded using the glasses.

NCT ID: NCT05814211 Completed - Clinical trials for Urinary Incontinence

Clinical Trial of New Intermittent Single-use Catheter

Start date: August 4, 2023
Phase: N/A
Study type: Interventional

A multi-centre, open-labelled, randomised, crossover design. The total study duration for the individual subject will be approximately 4 weeks, consisting of four site visits and two 2-week test periods at home. Visits 0 and 1 can be performed on the same day. For visit 2 and 3, 2 catheterisations will be performed in a hospital setting (one HCP catheterisation and one self-catheterisation) for bladder emptying and user experience assessments. Visit 1 and 2 are followed by a home-use test period, followed by visit 3 which terminates the study.

NCT ID: NCT05810753 Completed - Malnutrition Clinical Trials

Oral Nutritional Supplementation and Community-dwelling Older Adults: a Feasibility Study

SPOONful
Start date: May 20, 2023
Phase: N/A
Study type: Interventional

The goal of this study is to assess the feasibility and acceptability to community-dwelling older adults of implementing a precise prescription of oral nutritional supplementation (the SPOONful intervention).

NCT ID: NCT05810337 Completed - Clinical trials for Glucose Metabolism Disorders

Splenda: Effects on Blood Glucose Concentration, Appetite Scores and Subsequent Energy Intake

Start date: January 18, 2023
Phase: N/A
Study type: Interventional

This study investigates the effects of Splenda, an artificial sweetener powder containing sucralose, on post-prandial blood glucose levels, appetite scores and subsequent energy intake.

NCT ID: NCT05806190 Completed - Clinical trials for Diabetes Mellitus, Type 1

Hypoglycaemia (Low Blood Sugar) in Adults With Diabetes and Adrenal Failure

HYPO-DIAD
Start date: April 17, 2023
Phase:
Study type: Observational

The purpose of this study is to measure how often low blood sugars occur in people who live with both adrenal insufficiency (AI) and diabetes and need to take insulin. People who live with AI need to take steroid replacement tablets every day, for life. Two of the most common types of steroid replacement tablets are called prednisolone and hydrocortisone. Low blood sugar (hypoglycemia) is a very common side effect of taking insulin and can often be unpleasant, frightening and dangerous. People who have adrenal failure are also at risk of hypoglycaemia, although this is rare. It is not known whether taking steroids affects how often hypoglycaemia happens. The study has three aims: 1. To measure how often low blood sugars occur at night in people who live with with both adrenal insufficiency (AI) and insulin-treated diabetes 2. To compare how often low blood sugars occur in people taking prednisolone for their AI versus those taking hydrocortisone. 3. To compare the patterns throughout the day for low blood sugars in those taking prednisolone versus those taking hydrocortisone. The study will compare this information with results in people who have AI without diabetes. Participants will be given continuous glucose monitoring systems (Dexcom G6 devices) which are small wearable devices that measure glucose levels throughout the day and night. They will be asked to wear a device for 30 days. Participants will not be asked to make any changes to their usual medications or their diet.

NCT ID: NCT05804058 Completed - Joint Infection Clinical Trials

Biofilm Composition as a Predictive Biomarker for Prosthetic Joint Infection

Biofilms
Start date: July 1, 2019
Phase:
Study type: Observational

Prosthetic joint infection (PJI) represents one of the most common reasons for failure among hip and knee prostheses, with an incidence of around 1-2%. Infection can occur early (within days of surgery) or late (over a year after surgery), and no specific early markers for infection onset exist. Given the significant costs to the NHS for corrective revision surgery, the added suffering and risk to patients from surgery, and the risk of enhancing antimicrobial resistance through the use of broad-spectrum antibiotics, a more specific predictive test for early onset of infection is required.